Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) EV-to-EBIT : -0.84 (As of May. 22, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Paradigm Biopharmaceuticals's Enterprise Value is $38.74 Mil. Paradigm Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.21 Mil. Therefore, Paradigm Biopharmaceuticals's EV-to-EBIT for today is -0.84.

The historical rank and industry rank for Paradigm Biopharmaceuticals's EV-to-EBIT or its related term are showing as below:

PBIGF' s EV-to-EBIT Range Over the Past 10 Years
Min: -126.38 Med: 0 Max: 0
Current: -0.89

PBIGF's EV-to-EBIT is ranked worse than
100% of 423 companies
in the Biotechnology industry
Industry Median: 10.05 vs PBIGF: -0.89

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Paradigm Biopharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $73.98 Mil. Paradigm Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.21 Mil. Paradigm Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -62.47%.

Paradigm Biopharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Paradigm Biopharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals EV-to-EBIT Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-EBIT

Get a 7-Day Free Trial

-18.61

-49.32

-12.04

-4.73

-4.30

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial												-	-4.73	-	-4.30	-

Competitive Comparison of Paradigm Biopharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's EV-to-EBIT falls into.

Paradigm Biopharmaceuticals EV-to-EBIT Calculation

Paradigm Biopharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	38.743	/	-46.212
	=	-0.84

Paradigm Biopharmaceuticals's current Enterprise Value is $38.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paradigm Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.21 Mil.

Paradigm Biopharmaceuticals (OTCPK:PBIGF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Paradigm Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-46.212	/	73.9766048
	=	-62.47 %

Paradigm Biopharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $73.98 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paradigm Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.21 Mil.

Paradigm Biopharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

PAR:Australia

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).